课题基金 / 基金详情

项目摘要

项目成果

James E Crowe的其他基金

相似基金

相关文献

中文摘要
翻译
SERCEB的项目对单克隆有直接和预期的需求
英文摘要
The programs of the SERCEB have immediate and projected requirements for monoclonal antibodies (mAbs) for studies of pathogenesis, immune response, vaccine development, therapeutics and diagnostics. These reagents and bio-recognition elements will be vital to the success of proposed research projects. The nature and source of the monoclonal antibodies required will depend on the objective of the research program, ranging from murine monoclonal antibodies for immunohistochemistry and detection to human or humanized mouse antibodies for development of therapeutics. Broad expertise exists within the institutions of the SERCEB in mAb development, testing and use. The spectrum of expertise in mAb development includes human, mouse, humanized mouse, rhesus, and phage display human and mouse F abs and ScFv. Finally, the antibodies will be deliverables that may have immediate application in therapeutics and diagnostics. The proposed Core C is a distributed core that uses established labs at several institutions to provide each of the needed services. The Core will provide all of the biorecognition elements needed in the SERCEB and will develop them into new assays and biosensors. The core has four Specific Aims. Aim 1. Generate human mAbs to poxvirus neutralization targets and anthrax protective antigen. Aim 2. Generate high-quality mAb reagents for SERCEB research programs. Aim 3. Develop biosensors for diagnostics or detection of select agents using novel mAbs available in the SERCEB Aim 4. To develop a database and repository for mAbs within the SERCEB that can be shared across institutions, to facilitate the other scientific programs.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Human Monoclonal Antibodies for Encephalitic Alphaviruses
Human Monoclonal Antibodies for Encephalitic Alphaviruses
Structure based design of trimer interface epitope focused universal influenza vaccines
Structure based design of trimer interface epitope focused universal influenza vaccines
海外基金